MultiClonal Therapeutics (MCT), a personalized medicine startup founded by Frank McKeon and Wa Xian, announced it has been awarded a $750,000 Regenerative Medicine Research Fund (RMRF) grant and had a second article this year published in the prominent peer-reviewed scientific journal Nature. These funds from Connecticut Innovations will assist with the company’s efforts to develop personalized therapies for chronic lung diseases, such as COPD. McKeon and Xian will work to translate their technology for therapeutic uses with the help of UConn Professor of Medicine, Center for Bronchiectasis Care Director, Dr. Mark Metersky and Laura Haynes, UConn Professor of Immunology.
MCT is located at UConn's Technology Incubation Program (TIP) in Farmington, and the company’s founders cite the State of Connecticut, UConn, and TIP as great partners for commercializing their technology.
Full article.
For more information, contact: Jessica McBride at jessica.mcbride@uconn.edu